

Index

a

- abzymes (catalytic antibodies) 56, 211-213
- acute pancreatitis 157
- acute respiratory distress syndrome (ARDS) 148
- adaptive evolution 31
- adaptive landscape 57
- adenovirus 131
- adjuvant 154, 398
- ADP 72
- ADP-ribosylation factors (ARFs) 283
- affinity 371
- affinity capillary electrophoresis 335, 338
- affinity chromatography 324-325, 328, 330, 426
 - affinity capillary chromatography 327
 - affinity ligand 325
 - analyte capture 326
 - buffer composition 331
 - capillary internal diameter 331
 - chiral separation 332, 340
 - chiral stationary phase 332, 334
 - chromatographic support 325
 - column temperature 332
 - EDTA 331
 - EDTA gradient 327
 - eluent pH 332
 - elution conditions 325
 - immobilized ligand 325
 - immunoaffinity columns 325
 - ionic strength 331
 - mass transfer kinetics 340
 - microbead affinity chromatography 328
 - mobile phase pH 331
 - particle diameter 331
 - protein capture 327
 - recovery 327
 - salt concentration 332
 - stationary phase 325-326, 328-329, 340
 - streptavidin sepharose support 326
- affinity purification 122-123, 214
- affinity tag 122, 125, 128
- African trypanosomiasis (African sleeping sickness) 366
- age-related macular degeneration (AMD) 368, 387, 405, 443, 446, 453, 464
 - degenerating RPE cells 447
 - drusen 447
 - dry, or non-exudative AMD 447
 - lines of vision 455
 - neovascularization 457
 - ocular neovascularization 447
 - photodynamic therapy (PDT) 453
 - proliferative retinal neovascularization 451
 - regression of neovessels 457
 - wet AMD, also known as exudative or neovascular AMD 447
- agonists 270
- alcohol dehydrogenase (ADH) 78, 219-220
- allometric coefficients 392
- allosteric deoxyribozymes 290
- allosteric ribozymes; see aptazyme, allosteric (deoxy) ribozymes
- allosteric ribozymes 290
- AMD; see age-related macular degeneration (AMD)
- analyte–ligand interaction 325
- angiogenesis 140, 274, 349, 368, 443
- antibody 268-269, 303, 324-325, 349, 363, 366-367, 369-370, 383, 398-399, 426, 438, 463-464
- antibody fragments (scFv, Fab) 345, 348
- anticoagulation 149
- anticoagulation and thrombosis 368
- antidote 136, 151, 369, 383
- antigen–antibody complexes 335
- antisense 170, 186, 235, 268-269, 319, 353, 355-357, 381-382, 384-386, 388-389, 395, 398, 466
 - ^{99m}Tc-labeled antisense oligonucleotide 350

- antiterminator 180
- anxiety 160
- aptamer-competition screens 314
- aptamer conversion assay 316
- aptamer displacement 317
- aptameric sensor; see biosensor (aptasensor, sensor)
- aptamers as ligands for affinity chromatography 326, 330, 334
 - D-adenosine 332
 - adenosine 326, 330-331
 - adenosine and analogs 326
 - amino acids and derivatives 326
 - D-arginine 334, 340
 - enantiomers 326
 - flavin mononucleotide (FMN) 326, 331-332
 - HCV RNA polymerase and replicase 326
 - non-target analytes 326
 - non-target proteins 326
 - proteins 326
 - L-selectin 326-327
 - small molecules 326
 - thrombin 326, 328
 - L-tyrosinamide 332
 - D-tyrosine 334
 - tyrosine 334
 - vasopressin 326, 332
- aptamers as ligands in affinity capillary electrophoresis
 - antithrombin III 336, 338
 - HIV type 1 reverse transcriptase (HIV-1 RT) 336-337
 - IgE 336-337
 - thrombin 336-339
- aptamers for *in vivo* imaging 343, 346
 - radioiodinated (¹²⁵I) aptamer 359
 - tenascin-C 350, 359
- aptamers to
 - activated protein C 365
 - adenine 75
 - D-adenosine 332
 - L-adenosine 75
 - adenosine 74, 95, 305, 319, 326, 330-331
 - adenosine and analogs 326
 - adenosine-containing ligands 8
 - adenosylcobalamin 98
 - S-adenosyl homocysteine (SAH) 97
 - S-adenosyl methionine (SAM) 97-98, 204
 - adhesion molecules, receptors, and other cell surface proteins 364
 - ADP 304-305, 318-319
 - amino acids 74, 84, 95, 99
 - amino acids and derivatives 326
 - aminoglycosides 119, 124
 - amyloid beta 4 (Ab4) 365
 - angiogenin 364
 - angiotensin-1 (Ang1) 373
 - angiotensin-2 (Ang2) 137, 142, 274, 364, 369, 373
 - anti-AChR antibody, mAb198 370
 - anti-insulin receptor antibody MA20 138, 152
 - antibiotics 116
 - antibodies 365-366
 - antibodies/immunoglobulins 152
 - antithrombin III 336, 338
 - D-arginine 75
 - L-arginine 11, 75, 99-101, 196, 333-334
 - ARNO/cytohesin-2 283
 - aspartame 380
 - ATP 6, 8-9, 11, 74-75, 79, 95-97, 292, 300, 302, 380
 - ATP analogs 76
 - autoantibodies 370
 - B12 (cyanocobalamin) 6, 75, 98
 - B52 (splicing factor) 272, 368
 - bacteriophage T4 DNA polymerase 461
 - basic fibroblast growth factor (bFGF) 137, 142, 364, 369, 372, 374, 464
 - biotin 75, 99
 - caffeine 6, 75
 - cAMP 97, 306
 - carbohydrates 95, 102
 - cCMP 306
 - CD4 364
 - CD28 380
 - cell surface carbohydrates 104
 - cell surface receptor/cell adhesion molecules 155
 - cell surface receptors 366
 - cell surface targets 366
 - cellobiose 103
 - cellular components 95
 - cellulose 103
 - cGMP 296, 306
 - chloramphenicol (peptide antibiotic) 118, 119, 125
 - cholic acid 108
 - Cibacron Blue 3GA 109, 110
 - L-citrulline 11, 75, 99, 196
 - coagulation cascade components 365
 - coagulation factor IXa (FIXa) 369
 - cobalt ions 306
 - cocaine 107-108
 - coenzyme A (coA) 76-77, 97-98

- coenzymes 74
- cofactors 97
- complement C5 139, 157, 365, 371, 401-402, 405
- CTLA-4 138, 154, 274, 364, 367
- cyanocobalamin 6, 75, 98
- 3',5' cyclic-monophosphates 296
- 3'5'-cyclic-GMP 297
- cytohesin 1 271
- cytohesin 1 (Sec7 domain) 282-283, 314, 317, 365, 368
- cytokine/growth factors 140, 364, 375
- cytotoxic T-cell antigen 4 (CTLA-4) 138, 154, 274, 364, 367
- L-dopa 101
- dopamine 101
- E2F1 protein 146
- extracellular domain of HER3 375
- extracellular membrane proteins 139
- extracellular regulated kinase 2 (ERK2) 314, 365
- factor VIIa (FVIIa) 138, 151, 365, 369
- factor IX (FIX) 151
- factor IXa 138, 274, 365, 405
- fibronectin 156
- flavin 79, 98
- flavin moiety 99
- flavin mononucleotide (FMN) 95, 98-99, 112, 292-294, 300, 306-307, 326, 331-332
- flavin-adenine diphosphate (FAD) 11, 77, 98-99
- fluorescein 110-111
- fluorescent dyes 95, 109
- G protein-coupled receptor kinase 2 (GRK2) 314
- gonadotropin-releasing hormone (GnRH) 274
- growth factors 375
- GTP 6, 11-13, 375
- guanine 75, 96, 204
- guanosine 75
- guanosine monophosphate (GMP) 11
- HCV NS5B 365
- HCV RNA polymerase and replicase 326
- heparin binding targets 363
- heparin-binding proteins 372
- heparin sulfate 156
- hepatitis C ΔNS3 138
- hepatitis C NS3 138, 147, 282
- hepatitis C virus (HCV) RNA polymerase and replicase 328
- HER3, extracellular domain 364, 367, 375
- HIV gp120 365
- HIV integrase 365
- HIV-1 regulatory protein 367
- HIV-1 Rev ARM 299
- HIV-1 Rev peptide 6
- HIV-1 Rev protein 137, 271, 281, 285, 303-304, 307, 314, 316-317, 365
- HIV-1 reverse transcriptase (HIV-1 RT) 137, 145, 281, 285, 336-337, 365, 375
- HIV-1 surface envelope glycoprotein 120 (gp120) 367
- HIV-1 Tat 137, 144, 271, 365
- HIV-2 Tat 137
- Hoechst dye 33258 110-111, 121
- hTSA 364
- human epidermal growth factor receptor-3 (HER3) 367
- human neutrophil elastase (HNE) 138, 148, 365, 382
- Human non-pancreatic secretory phospholipase A₂ (hnp-s-PLA₂) 139, 157
- human OSM 373
- ICAM-1 375
- Immunoglobulin E (IgE) 138, 153, 336-337, 365, 369, 376
- α₁β₂-integrin, cytoplasmic domains 271
- interferon-γ 137, 142
- intracellular targets 367
- isoleucine 83
- L-isoleucine 101
- kanamycin A (aminoglycoside) 124
- kanamycin B (aminoglycoside) 124
- keratinocyte growth factor (KGF) 364, 372, 377
- laminin 156
- LFA-1 (CD18) 364
- lipoproteins 139
- lividomycin (aminoglycoside) 124
- lumiflavin 98
- lysozyme 307
- mAb 20 (anti-insulin receptor antibody) 365, 370
- mAb G6-9 (anti-DNA antibody) 365
- mAb198 (anti-AChR antibody) 153, 365
- malachite green 6, 110-111
- MAP kinase ERK 270
- MAP kinase, pERK 270
- MAP kinase ERK2 304
- MCP-1 364, 369
- metal ions 74
- monoclonal antibody to acetylcholine receptor 138
- MS2 coat protein 6
- NAD 97-98

- NAD⁺/ATP 77
- NAD⁺ 74
- NAD(P) 95
- natural products 105
- neomycin 117, 119
- neomycin B (aminoglycoside) 124
- neuropeptide Y 364
- NFκB 137, 146-147, 271, 380
- NGF 364
- nicotinamide cofactors 98
- NMN 98
- NMN/NAD 75
- non-target analytes 326
- non-target proteins 326
- nucleic acid binding proteins 144
- nucleic acid structures 167
- nucleocapsid (NC) protein of HIV-1 282
- nucleotide 95
- nucleotide factors 74
- oncostatin M (OSM) 364, 369
- organic dyes 109
- organic molecules 281
- paromomycin 124
- peptide antibiotic viomycin 119
- peptide hormones 366
- L-phenylalaninamide 102
- L-phenylalanine 101
- pigpen 364, 366
- platelet-derived growth factor (PDGF) 137, 143, 273-274, 276, 313, 315, 349, 364, 372, 374, 377, 403, 405, 464
- porphyrins 74
- prion protein PrP^{Sc} 139, 158
- prostate-specific membrane antigen (PSMA) 139, 156, 350, 364, 367, 375
- protein 131, 281, 299, 326
- Raf-1 RBD 365
- Reactive Blue 4 110
- Reactive Brown 10 110
- Reactive Green 19 110
- Reactive Red 120 110
- Reactive Yellow 86 110
- riboflavin 75, 98
- RNA polymerase II 281
- Sec7 domain of cytohesin-1 282-283, 314, 317, 365, 368
- L-selectin 138, 326-327, 350, 364, 367, 371-372, 374-375, 377, 402-403
- L-selectin/IgG fusion protein (LS-Rg) 155
- P-selectin 138, 155, 364, 367, 371-372, 374
- selectins 363
- sephadex 95
- sephadex G-100 104
- serine proteases 147
- sialyl Lewis X (sLe^x) 104
- sialyllactose 104, 381
- signaling mediators 365
- small molecules 95, 326
- small organic dyes 6
- small peptides 74
- special elongation factor (Se1B) 281
- splicing factor B52 272, 281, 368
- streptomycin (aminoglycoside) 117, 119, 122, 128
- substance P 365, 371
- subunit p50 147
- sulforhodamine B 110-111
- T4 DNA polymerase 132, 211
- TAR RNA 171-172
- target binding 45
- tenascin-C (TN-C) 157, 274, 346, 350, 353, 359-360, 364, 367
- tetracycline (peptide antibiotic) 118-119, 121
- TGFβ1 364
- TGFβ2 364
- theophylline 17, 75, 105-106, 112-113, 292, 296-297, 300, 306-308
- thrombin 6, 138, 149, 274, 300-301, 326, 328, 330, 336-339, 349, 353, 359, 365, 369, 373, 378, 383, 389, 400-401, 405, 463-464
- tobramycin 124, 128
- transcription Factor E2F 145
- transcription factor NFκB 282
- thrombospondin 156
- TNF, tumor neurosis factor 274
- tobramycin (aminoglycosides) 117
- transcription factor E2F 137
- *Trypanosoma brucei* (flagellar pocket protein) 364
- *Trypanosoma brucei* VSD protein 364
- *Trypanosoma cruzi* 139, 156
- *Trypanosoma cruzi* cell surface receptor 364
- L-tryptophan 101
- L-tyrosinamide 102, 332
- D-tyrosine 101
- L-tyrosine 101
- L-valine 75, 101
- vascular endothelial growth factor (VEGF) 137, 140, 305, 314, 349, 364, 368, 371-372, 374, 377, 381, 383-384, 387, 405, 443, 464
- vasopressin 326, 332, 364
- VEGF-A 274
- viomycin (peptide antibiotic) 117, 126
- viral coat proteins 366
- viral proteins 365

- viruses 281
 - Vitamin B₁₂ 204
 - wheat germ agglutinin (WGA) 313-315
 - xanthine 96
 - YPEN-1 cells 366
 - aptamers with catalytic properties
 - biphenyl isomerization 213
 - cholesterol esterase activity 213
 - porphyrin metallation 213
 - aptasensor; see biosensor (aptasensor, sensor)
 - aptazyme, allosteric (deoxy) ribozymes 16, 56, 79, 290, 303-304, 318
 - allosteric hammerhead ribozyme 106
 - aptamer-controlled ribozyme 17
 - array 306-307
 - ATP-dependent ligase 79
 - Boolean logic gates 306
 - cAMP 79
 - cGMP 79
 - communication module 294
 - deoxyaptazyme 301
 - effector activation 295
 - FMN aptamer motif 99
 - hammerhead ribozyme pool 296
 - molecular beacon 106
 - molecular computation 306
 - rational design 292
 - ribozyme ligase 106
 - scheme for an effector-activated aptazyme 295
 - self-cleaving aptazyme 18
 - theophylline aptamer 17, 106
 - theophylline-dependent ligase 79
 - use *in vivo* 308
 - aptazyme effector
 - adenosine 305, 319
 - ADP 304-305, 318-319
 - ATP 292, 300-302
 - cAMP 306
 - cCMP 306
 - cGMP 296, 306
 - cobalt ions 306
 - 3',5' cyclic-monophosphates 296
 - 3'5'-cyclic GMP 297
 - Cyt18-dependent 299
 - flavin mononucleotide (FMN) 292-294, 300, 306-307
 - HIV-1 reverse transcriptase (RT) 285
 - lysozyme 307
 - MAP kinase ERK2 304
 - non-nucleic acid effectors 291
 - non-oligonucleotide effectors 292
 - oligonucleotide 291
 - peptide 292, 296, 300
 - protein 292, 296, 299
 - Rev ARM 299
 - Rev protein 285, 303-304, 307
 - small organics 292, 296
 - theophylline 17, 106, 292, 296-297, 300, 306-308
 - thrombin 300-301
 - aptazyme, catalytic domain
 - cleavases 305
 - deoxyribozyme ligase 302
 - 8–17 deoxyribozymes 292, 305
 - 10–23 deoxyribozymes 292
 - group I ribozyme 292
 - hairpin 292, 300
 - hammerhead 292, 296-297, 301, 303-304, 306-307
 - HDV 292
 - L1-ligase 293-294, 296-297, 306-307
 - ligase 292-293, 299, 305
 - self-splicers 305
 - signaling aptazyme 303
 - *trans*-acting hammerhead 292
 - X-motif ribozymes 292
 - aptogenicity 371
 - ARC 127; see PDGF-BB aptamer ARC 127
 - ARC183; see thrombin aptamer ARC183
 - ARC187; see complement C5 aptamer
 - ARDS 157
 - area under the concentration–time curve, AUC 388
 - arthritis 148
 - asthma 369
 - atherosclerosis 356
 - ATP 72
 - autoimmune disease 142, 368-369
 - autoimmunity 152, 373
 - autoradiography 303
 - avidity 194
- b**
- bacterial peritonitis 157
 - base stacking 312
 - beacons 318
 - bifunctional kissing aptamer 177-178
 - biliary excretion 390
 - binding analysis 133
 - binding kinetics 373
 - binding pocket 196, 200, 213
 - bioanalytical methods
 - capillary gel electrophoresis (CGE) 395
 - hybridization-based ELISA-type assays 395
 - liquid scintillation counting (LSC) 393

- LSC 395
 - mass spectrometry methods such as MALDI-TOF 395
 - quantitative nucleic acid-intercalating dye (QNID) fluorescence assays 395
 - quantitative whole-body autoradiography (QWBA) 393, 395
 - radioimmunoassay (RIA) 396
 - bioavailability 135, 347, 349, 391
 - biodistribution 346, 387-390, 392, 396
 - bioinformatic approach 196, 201
 - biomarker discovery 465
 - biosensor (aptasensor, sensor) 107-108, 112, 240, 285, 290, 303, 305-306, 318, 324, 426
 - biostability 418, 437
 - biosynthesis of nucleotides 219
 - blindness 446
 - breast cancer 159, 429
 - Bruch's membrane 447
 - bypass vein grafts 146
- c**
- CABG; see coronary artery bypass graft (CABG)
 - cancer 141-142, 403
 - VEGF antibody (avastin) 445
 - capillary electrochromatography (CEC) 328, 331, 340
 - capillary electrophoresis (CE) 324
 - laser-induced fluorescence detection 335
 - mobility 337
 - separation efficiency 337
 - cardiopulmonary bypass (CPB) 149
 - cardiovascular diseases 350
 - atherosclerosis 145
 - cardiac hypertrophy 145
 - cardiac intimal hyperplasia 145
 - catalysis 212
 - catalytic activity 4
 - catalytic antibody 56, 211-213
 - catalytic center 213
 - catalytic pocket 214
 - cell adhesion 271
 - cell membranes 349
 - cell trafficking 155
 - cell–cell adhesion 366
 - cellular biodistribution 393
 - cellular uptake 348, 368
 - 13-amino-acid fragment (Tat) of the HIV Tat protein 379
 - 16-amino-acid sequence derived from the third helix of the *Drosophila* antennapedia (Ant) homeotic protein 379
 - cell-permeating peptides 389
 - lipophilic moieties 389
 - short, positively charged cell-permeating peptides composed of polyarginine (Arg_n) 379
 - Chagas' disease 156
 - chelator 352
 - bifunctional 353
 - DO3A 354, 359
 - DOTA 352, 354, 356, 358
 - DTPA 350-352
 - EDTA 376
 - ⁶⁸Ga-DO3A-TTA1 360
 - HYNIC 350-351
 - MAG₂ 359
 - MAG₃ 350-352, 356
 - peptidergic 352
 - chemical interference 176
 - chemical trapping 214
 - chemokines 369
 - chemotactic growth factor 143
 - chemotherapeutics 276
 - chimeric RNA expression system 281
 - chimeric tRNA–RRE aptamer 145
 - chiral inversion 334
 - chiral principles 417
 - chirality 212
 - asymmetric carbon 420
 - homochiral polymer 427
 - homochirality 437
 - lock-and-key stereocomplementarity 422
 - optical antipodes 419
 - polyaffinity theory 420
 - shape complementarity 420
 - stereocomplementarity 420
 - stereoisomers 420
 - circular dichroism (CD) 426
 - circulation time 349
 - clearance 149, 349, 388-390
 - coagulation cascade 149, 151, 369
 - coenzyme 72, 80-83, 191, 204
 - coenzyme A 72
 - colorectal cancer 369
 - combinatorial chemistry 461, 467
 - combinatorial library 4, 229
 - compartmental modeling 388
 - competition assay 313
 - competition problem 55
 - competitive approach 325
 - complement activation 157
 - complement C5 aptamer ARC 187 401-402
 - complement system
 - alternative pathway 401
 - classical pathway 401

- lectin pathway 401
 - confocal microscope 328
 - conformation 136
 - controlled-release
 - encapsulation 391
 - poly(lactic-co-glycolic) acid (PLGA) 384
 - cooperative binding 203
 - coronary artery bypass graft (CABG) 373
 - CABG 383, 400, 402
 - CABG surgery 389
 - Creutzfeldt–Jakob disease 158
 - crystallization 422
 - crystallography; see X-ray crystallography
 - cyclic AMP 72
 - cytochrome P450 family 390
 - cytokines 369
 - cytomegalovirus (CMV) promoter 185
 - cytoskeletal rearrangement 271
 - cytoskeleton 283
 - cytotoxins 366
- d**
- Darwinian evolution 14, 20
 - Darwinian selection 30
 - decoy 131, 144–145
 - delivery 368
 - deoxyribozyme (DNAzyme) 3, 7, 220, 228, 229
 - ATP-utilizing DNAzyme NTP-A1 250
 - bipartite DNAzymes 245
 - bipartite I 245
 - bipartite II 245
 - class I capase deoxyribozyme 251–252
 - 8-17 deoxyribozyme 233–234, 240–244, 257, 292
 - 10-23 deoxyribozyme 233–238, 292
 - deoxyribozyme ligase 302
 - deoxyribozymes for thymine dimer repair 253
 - DET22-18 245–246
 - DNA enzymes catalyzing the formation of phosphorothioester bond 252–253
 - DNA enzymes with foreign functionalities 254
 - DNA ligase 301
 - DNA ligating DNAzyme 231, 252
 - DNA-cleaving deoxyribozyme 248
 - DNA-cleaving DNA enzymes 248
 - DNA-modifying DNA enzymes 249
 - 8-17 DNAzymes 235
 - DNAzyme-catalyzed DNA ligation 252
 - DNAzymes for thymine dimer repair 254
 - fluorescence-signaling DNAzyme DET22-18 245–246
 - 10-28 N-glycosylase DNAzyme 248
 - histidine-dependent DNAzyme 245
 - ligase deoxyribozyme, 7Q10 247
 - Mg²⁺-dependent RNA-cleaving DNA enzyme 230
 - Mg²⁺-dependent RNA-cleaving DNAzyme 233
 - Mg5 deoxyribozyme 242
 - Pb²⁺-dependent RNA-cleaving DNAzymes 230
 - porphyrin metallating DNAzymes 233
 - RNA cleavage reaction 229
 - RNA-cleaving deoxyribozyme 9₂₅-11 256
 - RNA-cleaving deoxyribozymes 243, 245–246, 255
 - RNA-ligating deoxyribozymes 246–247
 - self-capping (or self-adenylating) DNAzymes 251
 - self-phosphorylating deoxyribozymes Dk1, Dk2 251
 - self-phosphorylating DNAzymes 250
 - UV1C 254
 - Zn²⁺/Cu²⁺-dependent DNA-ligating DNAzymes 231
 - depot 384
 - diabetes 444
 - diabetic retinopathy 141–142, 403, 457
 - fibrovascular proliferation 448
 - loss of pericytes 448
 - microaneurysms 448
 - microvascular changes 448
 - proliferative diabetic retinopathy 448
 - proliferative retinal neovascularization 451
 - retinal edema 448
 - retinal hemorrhage 448
 - Diels-Alderase 224
 - diastereoselectivity 222
 - enantioselective transformations 221
 - enantioselectivity 221
 - immobilization 223
 - mirror-image L-ribozyme 221
 - modeled three-dimensional structure 223
 - probing experiments 223
 - refined secondary structure 223
 - secondary structure 222
 - dimerization initiation site (DIS) 172
 - dimerization signal 168
 - direct protein inhibitor 265
 - discrimination 329

- l-DNA 421, 434, 437
 - l-deoxyuridine 421
 - DNA enzyme; see deoxyribozyme (DNAzyme)
 - DNA nanomotor 239
 - DNA shuffling 6
 - DNA–RNA–protein world 219
 - domain approach 428
 - Doppelgänger proteins 420
 - Drosophila melanogaster 180
 - drug development 265
 - drug discovery 265
 - drug screening 287
 - drug target 268–269
 - drugability 280
 - dynamic nanomaterials 240
- e**
- E2F DNA decoy aptamer
 - *ex vivo* pressure-mediated transfection 146
 - bypass vein grafts 146
 - intimal hyperplasia 146
 - phase III study 146
 - electrochromatography 325
 - electron transfer 220
 - electrophoretic mobility shift assay 174, 184
 - ELISA 324, 432
 - ELONA 324
 - emphysema 148
 - enantioselectivity 332
 - endometriosis 159, 429
 - 3'-endo sugar pucker 371
 - energy function 57
 - entropy 14
 - epitopes 281, 321
 - equilibrium dialysis assays 429
 - equilibrium dissociation constants 370
 - error prone 31
 - error threshold 30, 68–70
 - error threshold of replication 56
 - evolutionary adaptation 56
 - evolutionary design 35, 42, 46
 - breeding of molecules 49
 - rational design 49
 - replication assays 49
 - excretion 347
 - expression vectors 236
 - extracellular targets 349
- f**
- FAD 72
 - FDA; see Food and Drug Administration (FDA)
 - Fischer, Emil 420
 - fitness landscape 54, 57–58, 60–62, 64, 85
 - fitness value 57
 - flow cytometry 324
 - fluorescence signaling 246, 319
 - fluorescence intensity (FI) 314
 - fluorescence lifetime (FLI) 314
 - fluorescence polarization (FP) 314, 316
 - fluorescence resonance energy transfer (FRET) 303–304, 319
 - Food and Drug Administration (FDA) 363, 383–384, 405, 443, 446, 452
 - formulations 383
 - polyalginate/polylysine microparticles 386
 - FRET; see fluorescence resonance energy transfer (FRET)
 - function landscape 56, 85
 - functional sequence variant 13
- g**
- gene expression 268, 272
 - gene knockout 268
 - gene regulation 193
 - gene therapy 168
 - genetic algorithm 57
 - genetic engineering 290
 - genotoxicity 397
 - genotype and phenotype 30
 - genotype–phenotype map 39
 - ghrelin-Spiegelmer NOX-B11
 - acute food intake 432
 - c-Fos-like immunoreactivity 432
 - GH release 432
 - specificity to the octanoylated form of ghrelin 431
 - weight loss in diet-induced obese mice 432
 - glioblastoma U251 360
 - glioblastoma 359, 366
 - glomerular filtration 392
 - glomerulonephritis 403
 - experimental 144
 - mesangioproliferative 143
 - glutamyl-tRNA synthetase 84
 - glycosylation 383
 - GNRA tetraloop receptor 168
 - gram-negative organisms 196
 - gram-positive organisms 192, 196
 - green fluorescence protein (GFP) 121
 - guanine nucleotide exchange factors (GEFs) 282
 - guanine riboswitch aptamer
 - complex with hypoxanthine 197
 - purine metabolism 198

- secondary structure 197
 - three-dimensional structure 197
- h**
- half-life 366, 378-379, 381, 383, 387-390, 392, 396, 420
 - Hamming distance 31, 33, 35, 49
 - handedness 421
 - hemorrhage 151
 - heparin 143, 152
 - hepatic clearance 390
 - hepatitis 147
 - hepatitis C virus (HCV) 179
 - heteropolymeric macromolecules 15
 - heteropolymers 22
 - hexitol nucleic acid (HNA) 181-183
 - high-performance liquid chromatography (HPLC) 340
 - high-throughput screening (HTS) 284, 286, 311, 319-321
 - Hill coefficient 201
 - Hill equation 201
 - L-histidine 78
 - HIV 131
 - replication 144-145, 304, 314
 - HIV therapy 145
 - HNA; see hexitol nucleic acid (HNA)
 - HNA–RNA chimeras 182-183, 185
 - HNA–RNA chimeric 184
 - homopurine–homopyrimidine tracts 168
 - Hoogsteen 167
 - HTS; see high-throughput screening (HTS)
 - hydrogen bonding 312
- i**
- IFP; see interstitial fluid pressure (IFP)
 - imaging modalities
 - computed tomography (CT) 343, 361
 - magnetic resonance imaging (MRI) 343-344
 - optical imaging (OI) 343-344
 - positron emission tomography (PET) 343-345, 349, 351-358, 360-361
 - single photon emission computer tomography (SPECT) 343, 345, 351-354, 356-357, 360
 - ultrasound 343-344
 - X-Ray/CT 344
 - imidazole 77
 - immune responses 349
 - immune system 213
 - immunogenicity 134, 159, 397-398, 421, 432-433
 - inflammation 350, 359, 368-369, 393
 - inflammatory disease 142, 155
 - informational complexity 12
 - in silico* evolution
 - fitness landscape 44-45
 - flow reactor 42
 - fluctuations 44
 - optimization process 44
 - optimization trajectory 44
 - population size 44
 - simulated population 43
 - in silico* models 312
 - interference RNA; see siRNA (small interference RNA, RNAi)
 - interferon 131
 - interferon response 269
 - internal ribosome entry site (IRES) 179
 - internalization 348
 - interstitial fluid pressure (IFP) 273, 275
 - intimal hyperplasia 146
 - intrabodies 268, 281
 - intracellular proteins 284
 - intracellular targets 271
 - intramer to 280-281, 284
 - ARNO/cytohesin-2 283
 - B52 368
 - cytohesin-1 282-283
 - HIV-1 reverse transcriptase (RT) 281
 - LFA-1 (CD11a/CD18) 368
 - NS3 of hepatitis C virus (HCV) 282
 - nucleocapsid (NC) protein of HIV-1 282
 - Rev protein 281
 - RNA polymerase II 281
 - Se1B 281
 - Sec7 domain of cytohesin-1 368
 - special elongation factor 281
 - splicing factor B52 281
 - transcription factor NFκB 282
 - intramer expression system 281
 - inverse folding algorithm 50
 - in vitro* evolution 84, 219, 257
 - in vitro* selection 168, 173, 204, 229, 241, 243, 245-246, 248-249, 253, 255, 290, 299-301, 305, 324, 430
 - allosteric selection 17
 - automation 281
 - ¹⁰B-containing aptamers 380
 - biased (or doped) selection 371
 - build species cross-reactivity 373
 - by binding to transition state analogs 56
 - by compartmentalization 18, 20
 - chimeric approach 112
 - chiral principles 437

- counterselection 96, 122, 283
 - covalent inhibitor 148
 - cross-SELEX approach 373
 - degenerated RNA library 282
 - *de novo* creation of ribozymes 213
 - direct selection (techniques) 232, 256
 - direct selection with linker-coupled reactants 214-215, 221
 - DNA-SELEX 418
 - encapsulated selection 22
 - Fluorescence-activated cell sorting (FACS) based selection 18-20
 - *in vitro* aptazyme selection 293
 - mirror-image *in vitro* selection 424
 - mirror-image evolutionary techniques: selection–reflection 422
 - multiple-turnover catalyst 18
 - of protein enzymes 19
 - partitioning 374
 - 5-(1-pentynyl)-2'-deoxyuridine 380
 - phosphorodithioate-containing aptamers 380
 - phosphorothioate SELEX 379
 - photo-activated cross-linking nucleotide 465
 - post-SELEX 371
 - process of discovery 266
 - restrictive selection protocol 96
 - RNA-SELEX 418
 - scheme 5, 120, 229, 231-232, 234
 - scheme for an effector-activated aptazyme 295
 - SELEX 72, 101, 118, 132-133, 144-146, 149, 154, 156-157, 167, 169-170, 172, 174, 181, 184, 211, 213, 220, 276, 281, 314, 324, 340, 346-347, 349-350, 359, 363, 366-367, 369-371, 373-375, 380, 417-418, 425-426, 428-429, 438, 461-462, 466-467
 - sequential SELEX 373
 - subtractive SELEX process 372
 - tailored-SELEX 159
 - tailored-SELEX process 430
 - TNA selection 21
 - toggle approach 150
 - toggle SELEX 136, 367
 - TSA approach 213
 - in vivo* diagnostics (*in vivo* imaging) 463, 465
 - ¹⁸F-fluorodeoxyglucose (FDG) 344
 - anatomical imaging 344
 - computed tomography (CT) 343, 361
 - contrast agents 344
 - intracellular targets 347
 - magnetic resonance imaging (MRI) 343-344
 - molecular imaging 343
 - oncological PET imaging 360
 - optical imaging (OI) 343-344
 - positron emission tomography (PET) 343-345, 349-361
 - signal-to-noise ratio 345-348
 - single photon emission computer tomography (SPECT) 343-345, 351-354, 356-357, 359-360
 - spatial resolution 361
 - tumor-to-blood ratio 345, 357
 - tumor-to-normal tissue ratios 345
 - tumor-to-organ ratio 348
 - ultrasound 343-344
 - X-Ray/CT 344
 - in vivo* imaging; see *in vivo* diagnostics (*in vivo* imaging)
 - internal ribosome entry site (IRES) 185
 - in vivo* validation 267
 - ionic interactions 312
 - iontophoresis 385
 - ischemia-reperfusion 148
 - ischemia-reperfusion injuries 146
 - isoelectric points 371
 - isotopic assays 314
- k**
- key and lock hypothesis 420
 - kinetic folding 33
 - kinetic model 30
 - kinetic parameters 195
 - kinetic theory of molecular evolution 30
 - kissing complexes 186
 - Kupffer cells 381
 - Kuru disease 158
- l**
- label-free techniques 303
 - lariat RNA molecules 247
 - leukemia 143
 - leukocyte adhesion 317
 - library design 8ff., 11-12, 155
 - 2'-amino-modified RNA 151
 - 2'-aminopyrimidine-modified RNA 153-154
 - backbone modifications 376
 - communication module 294
 - coupled of CoA to 5'-end 219
 - degenerated RNA library 282
 - direct selection with linker-coupled reactants 214-215

- 2'-fluoropyrimidine-modified RNA 150, 155, 157
- hammerhead ribozyme pool 296
- internal stem–tetraloop 13
- L1-N50 pool 299
- length requirements in the random regions 463
- libraries of 2'-modified oligonucleotides 376
- modular design 293
- partially designed library 13
- 5-(1-pentynyl)-2'-deoxyuridine 380
- phosphorodithioate-containing libraries 379
- photo-activated cross-linking nucleotide 465
- primerless RNA library 430
- random region 132, 169
- stable internal tetraloop 12
- tailored SELEX 430
- life
 - ancestors of 14
 - definition of 14
 - physical chemistry of 14
- 2'-5' linkages 247
- lipofection 284
- LNA–DNA chimeras 182-183, 185
- locked nucleic acid (LNA) 181-183
- luciferase reporter gene 283
- lung inflammation 148
- lymph node metastasis 344
- lymphocyte trafficking 367, 403
- lymphoma 143
- m**
- Macugen (pegaptanib sodium) 140, 160, 363, 369, 377, 382-384, 405, 438
 - adverse events 455-456
 - age-related macular degeneration (AMD) 133, 141, 387, 398, 443, 464
 - antigenic response 398
 - deoxythymidine 3'-3'-linked 433
 - diabetic retinopathy 457
 - endophthalmitis 456
 - FDA 437
 - genotoxicity 397
 - immunogenicity 397
 - intravitreal injection 141, 398, 453
 - lines of vision 455
 - liposome-anchored 381
 - macular edema 457
 - maximum tolerated dose (MTD) 397
 - Miles assay 452
 - model of diabetic blood–retinal barrier breakdown (BRB) 452
 - murine model of neuroblastoma 142
 - neovascular AMD 456
 - neovascularization 453
 - no-observable-adverse-effect-level (NOAEL) 397
 - ocular neovascularization 141
 - 40 kDa PEG moiety 433
 - Phase I 398, 433, 452-453, 464
 - Phase II 141, 387, 452-453
 - Phase III 141, 387, 452, 454
 - plasma residence time 381
 - 5'-40 kDa-polyethylene glycol-terminated 387
 - preclinical studies 452
 - primary efficacy endpoint 455
 - retinal neovascularization 141
 - retinopathy of prematurity (ROP) 453
 - safety profile 456
 - secondary efficacy endpoint 455
 - single dose 397
 - specificity 450
 - subchronic repeated dosing toxicity studies 397
 - vascular endothelial growth factor (VEGF) 364, 368, 371
 - VEGF inhibition 450
 - VEGF pathway 464
 - VEGF₁₆₅ 452
 - visual acuity 453
- major histocompatibility complex (MHC) 142
- malachite green aptamer
 - aptamer in tandem 112
 - aptameric sensor 112
- chromophore-assisted laser-mediated inactivation (CALI) of RNA transcripts 111
- MALDI-TOF analysis 328
- manufacturing
 - Caruthers patent 399
 - cGMP manufacturing infrastructure 399
 - cost of phosphoramidites 398
 - large-scale chemical plants 399
 - material costs 398
 - solid support chemistries 399
- mathematical model 29
- matrix metalloproteinases 445
- maximum lifespan potential (MLP) 392
- maximum observed plasma concentration, C_{max} 388
- maximum tolerated dose (MTD) 397
- mechanism-of-action 265, 270
- medicinal chemistry 265, 313

- melting curve 183
- mesangioproliferative glomerulonephritis 404
- metabolic stability 389
- metabolism 363, 390
- metabolite-binding RNA; see riboswitch (metabolite-binding RNA)
- metal requirement 7
 - Ca²⁺ 251
 - Cu²⁺ 248, 250
 - cupric ion-dependent 220
 - divalent lead 229
 - divalent metal cofactor 229
 - divalent metal ions 239, 246
 - magnesium 169, 173, 184, 251, 331
 - Mg²⁺-dependent RNA-cleaving DNA enzyme 230
 - Mn²⁺ 250
 - Pb²⁺ ions 241
 - Pb²⁺-dependent RNA cleavage activity 240
 - Pb²⁺-dependent RNA-cleaving ribozymes 229
 - potassium 254
 - Zn²⁺ RNA structure 101
 - Zn²⁺/Cu²⁺-dependent DNA-ligating DNazymes 231
- Michaelis–Menten constant 232
- Michaelis–Menten kinetics 221
- microdialysis 331
- microRNA (miRNA) 286
- migraine 159, 430
- Miles assay 140, 452
- minimal binding motif 127
- minimal cell model
 - autocatalytic metabolic cycle 54
 - chemoton 54
 - replicative ribozymes 54
- minimal free energy 32
- mirror-image phage display 424
- mirror-image nucleic acids 418, 421
- mirror-image peptide (D-peptide)
 - cecropin 420
 - magainin-2 amide 420
 - melittin 420
 - rubredoxin 420
 - HIV-1 protease 421
- mirror-image peptide (D-peptide) aptamer to
 - amyloid peptide Aβ(1–42) 424, 438
 - 3-deoxy-α-L-manno-2-octulosonic acid 424
 - HIV envelope gp41 protein 424, 438
 - prokaryotic cell surface carbohydrates 424
 - L-sialo-disaccharide 424
 - sialic acid/KDO 438
 - Src homology 3 (SH3) domain of chicken Src 424, 438
- mirror-image proteins (D-protein) 420
- mitogen 143
- Mitscherlich, Eilhard 419
- modifications 140, 183, 376, 382
 - alkylamine 379
 - 3-(aminopropynyl)-7-deaza-deoxyadenosine 255-256
 - 2'-amino 8, 142, 153, 180, 347, 390, 418
 - 13-amino-acid fragment (Tat) of the HIV Tat protein 379
 - 16-amino-acid sequence derived from the third helix of the *Drosophila* antennapedia (Ant) homeotic protein 379
 - 5-amino analog 380
 - 5-aminoallyl-dU 255
 - 5'-amino modifier phosphoramidite 379
 - antennapedia peptides 382
 - backbone modifications 265, 376, 378
 - base modifications 380
 - 3' biotin 330, 359
 - 5'-biotin 231, 234, 326
 - biotin 366
 - C5-imidazole deoxyuridine 255
 - capping the 3' End 347, 378
 - capping the 5' End 379
 - cell-penetrating peptides 382, 389
 - cholesterol 152, 379, 381
 - 3'-cholesteryl phosphorothioate 381
 - conjugation 389
 - 3' end-blocking 359
 - 2'-deoxy-2'-fluoro 433
 - 5-(1-pentynyl)-2'-deoxyuridine 380
 - fatty acids 382
 - fluorine 305
 - 2'-fluoro 8, 142-143, 180, 270, 340, 347, 359, 387, 390, 397, 404, 418
 - 5'-(α-P-borano) GTP 380
 - high-molecular-weight polymers 389
 - highly positively charged peptides 382
 - 8-histaminyl-dA 255
 - hydroxymethyl group 305
 - inverted 3'-3' caps 390
 - 3'-inverted deoxythymidine (3'-idt) 135, 387, 403-404, 433
 - 3'-3' inverted nucleotides 236
 - 3'-inverted thymidine (3'-idt) 378
 - ³H-labeled 393-394
 - lipid-modified 381
 - lipophilic moieties 389
 - liposome surface 135
 - LNA-2'-O-methyl chimeric derivative 186

- locked nucleic acid (LNA) 181, 236, 347, 353, 378
 - MAG_3 -aminohexyl chelator 350
 - methyl phosphonates 381
 - methyl diester 347
 - methylphosphonate linkages 380
 - 2'-modification 135, 376, 378
 - non-nucleotide caps 378
 - non-nucleotide linker 179
 - non-nucleotide modifications 378
 - nuclease-resistant analogs 180
 - nucleobase-pairing systems 21
 - 2'-O-methyl 8, 135, 140, 143, 180-181, 185, 236, 270, 340, 347, 353, 355, 359, 371, 377, 385-387, 390-391, 393, 396-397, 403, 418, 433
 - P-borano linkages 380
 - 5'-PEG conjugation (0, 20, 30, and 40 kDa) 396
 - PEG linker 177, 214-215
 - peptide nucleic acids (PNAs) 347
 - peptide tags 382
 - phosphate substitutions 379
 - phosphoramidate 185
 - 3'-phosphorimidazolidine 231
 - phosphorodithioate 379
 - phosphorothioate 180, 236, 347, 355, 379, 381
 - photo-activated cross-linking nucleotide 465
 - photocleavable *o*-nitrophenyl group 215
 - PNAs 356-357
 - polyarginine 382
 - polycations 379
 - polyethylene glycol (PEG) 135, 273, 276, 347, 370, 379, 381, 384, 389, 392, 395, 432
 - 20 kDa polyethylene glycol (PEG) 266, 395
 - 30 kDa polyethylene glycol (PEG) 143, 266
 - 40 kDa polyethylene glycol (PEG) 266, 390, 404, 431, 433
 - 5'-40 kDa polyethylene glycol (PEG) 387, 403
 - polyethylene glycol (PEG) link 177, 214-215
 - polylysine 382
 - post-SELEX modification 347, 376-378, 418
 - post-synthesis coupling 379
 - pre-SELEX modification 418
 - primary amine 380
 - 5-propyne 385
 - proteins 379
 - pyrene 378
 - pyrimidine chemistry 466
 - radiolabeled 346, 349-351
 - radiolabeling 347, 351
 - 2'-ribose 2'-aminopyrimidine (rRaY) 377
 - 2'-ribose 2'-fluoropyrimidine (rRFY) 376, 403
 - short, positively charged cell-permeating peptides composed of polyarginine (Arg₇) 379
 - site-specific conjugation of a bifunctional chelator 351
 - split synthesis method 380
 - sugar modifications 389
 - Tat 382
 - 5-thiol analog of dU 381
 - thiol residues 380
 - thiol-modified DNA 305
 - 5'-(α -P-borano) UTP 380
 - modular nature of RNA 118
 - molecular beacon 180
 - molecular clock 42
 - molecular computation 240, 306
 - molecular modeling 167
 - mRNA (messenger RNA) 269, 280
 - multiple turnover 234, 242, 245
 - multivalent aptamer 368
 - mutagenized library 11
 - mutagenized pool 98
 - mutant 60-61, 65
 - mispair 63
 - mutant distribution 30
 - mutation
 - compensatory 56
 - multiple 60
 - neutral 56
 - one- or two-mutant molecules 68
 - single 60, 68
 - myasthenia gravis (MG) 153, 370
 - mycoplasma 14
 - myocardial infarction 146
- n**
- N^6 -ribosyladenine 78
 - N-K model 57
 - NAD 72
 - NADP 72
 - nanoparticles, DNA-functionalized 305
 - nanorobotics 240
 - natural aptamer 192, 465-466
 - NECEEM; see non-equilibrium capillary electrophoresis of the equilibrium mixture (NECEEM)

- neointima formation 146
 - neovascularization 141-142, 447, 451-453, 457
 - nephritis 147
 - neurogenic inflammation 430
 - neutral evolution 42, 45
 - neutral network 29, 39-45
 - neutrophil infiltration 148
 - neutrophil–neutrophil adhesion 367
 - nitrocellulose filter assays 402
 - NMR; see nuclear magnetic resonance spectroscopy (NMR)
 - no-observable-adverse-effect-level (NOAEL) 397
 - nociception 160
 - non-compartmental analysis (NCA) 388
 - non-equilibrium capillary electrophoresis of the equilibrium mixture (NECEEM), single-exponential function 338
 - non-small cell lung cancer (NSCLC) 344
 - NOX-B11; see ghrelin-Spiegelmer NOX-B11
 - nuclear magnetic resonance (NMR) 11, 96, 167, 172
 - nuclear magnetic resonance spectroscopy (NMR) 111, 126, 174, 176, 200, 284, 312
 - l-arginine 101
 - theophylline aptamer 105
 - nuclease degradation 135, 284
 - nuclease resistance 140, 183, 377, 380
 - NX1838; see Macugen (pegaptanib sodium)
 - NX1975; see PDGF aptamer NX1975
- o**
- obesity 432
 - l-oligonucleotides 333
 - oncology 350, 368
 - organic synthesis 224
 - origins of life 14 ff.
 - DNA–protein world 69
 - first biopolymers 15-16
 - genetic alphabet 81
 - genetic code 56
 - non-enzymatic replication 80
 - nucleic acid world 77
 - primordial metabolism 80
 - protein world 77, 79
 - replicability 81
 - replicative fidelity 81
 - RNA organism 17
 - translation 56
 - orthogonal cleavage 214
- p**
- pain 160, 430
 - Pasteur, Louis 419
 - PCR; see polymerase chain reaction (PCR)
 - PDGF aptamer NX1975 377
 - PDGF-BB aptamer ARC 127 277, 403
 - 2'-fluoropyrimidine 404
 - 3'-inverted deoxythymidine 404
 - 40 kDa PEG group 404
 - combination therapy using anti-VEGF and anti-PDGF-BB agents 405
 - human proliferative disease 404
 - interstitial fluid pressure (IFP) 404
 - mesangioproliferative glomerulonephritis 404
 - proliferative retinopathies 405
 - treatment of angiogenesis-mediated diseases 405
 - pegaptanib; see Macugen (pegaptanib sodium)
 - p-peptide; see mirror-image peptide (p-peptide)
 - p-peptide aptamer to; see mirror-image peptide (p-peptide) aptamer to
 - peptide bond formation 218
 - peptide library 300
 - peptide world 219
 - peptide-ligation techniques 421
 - permeation enhancers
 - sodium caprate 386
 - sodium chenodeoxycholate 386
 - sodium laurate 386
 - sodium ursodeoxycholate 386
 - phage display 382
 - bacteriophage particles 417
 - fd 417
 - filamentous phages 417
 - M13 417
 - random peptides 417
 - pharmacokinetics 135, 149, 269, 345, 349-350, 354-355, 381, 387-390, 392, 396
 - half-life 267, 403
 - pharmacological probe 267, 269-270, 273
 - pharmacology 270
 - phenotype 268
 - photoaptamer 465
 - photodynamic therapy (PDT) 141, 453
 - phylogenetic conservation 195
 - phylogeny 196, 199, 203
 - plasma concentration 388, 390
 - platelet aggregation 149
 - platelet–neutrophil adhesion 367
 - platelet–neutrophil association 374

- polymerase chain reaction (PCR) 133, 215, 229, 231, 294, 418
 population genetics 31
 post-transcriptional modification 72
 post-translational modification 280
 production 349
 prostate cancer 159, 429
 D-Protein; see mirror-image protein (D-protein)
 protein kinase (PKR) pathway 269
 protein space 57
 protein synthesis 203
 protein translation 269
 protein-protein interactions 366
 purine efflux pump 199
Pwo DNA polymerase 381
- q**
- Q β replicase 29
 quantitative whole-body autoradiograph (QWBA) 394
 quartz crystal microbalance (QCM) 303
 quasi-species 30, 68
- r**
- radioisotope 347, 366
 – ³H (H-3) 393, 394
 – ¹¹C (C-11) 353
 – ¹³N (N-13) 353
 – ¹⁵O (O-15) 353
 – ¹⁸F (F-18) 343-345, 350, 352-356
 – ⁶⁴Cu (Cu-64) 352, 354, 356, 358-359
 – ⁶⁸Ga (Ga-68) 343, 352-354, 360
 – ⁷⁶Br (Br-76) 353
 – ^{99m}Tc (Tc-99m) 343, 345-348, 350-352, 356-357, 359-360
 – ¹¹¹In (In-111) 343, 352-353
 – ¹²³I (I-123) 343, 352-353
 – ¹²⁴I (I-124) 352
 – ¹²⁵I (I-125) 346, 353
 random library 9
 random sequence 5
 rational design 35
 rational drug design 312
 reactions
 – acyl-transfer reactions 6
 – acylation 216
 – S-acylation 217
 – aldol reactions 212
 – alkylation 6, 216
 – N-alkylation 216
 – S-alkylation 217
 – amide bond formation 6, 211, 216
 – asymmetric carbon-carbon bonds 15
 – biphenyl isomerization 213, 216
 – σ -bond rotation 212
 – C-C-bond formation 6, 211, 216
 – C-metal bond formation 218
 – C-N bond formation 216
 – C-O bond formation 217
 – C-S bond formation (by Michael addition) 216
 – C-S-bond formation 211, 217
 – carbonate ester hydrolysis 217
 – cholesterol esterase activity 213
 – cleavage of amide bonds 211
 – cleavage of carboxylic ester bonds 211
 – cleavage of phosphodiester *in trans* 220
 – cyclization 71
 – cycloadditions 212, 221
 – Diels-Alder reaction 6, 212-214, 216, 221, 224, 427
 – DNA ligation 231, 252
 – DNA phosphorylation 250
 – DNA self-modification reactions 249
 – DNA depurination 216
 – β -elimination 249
 – excision 71
 – formation of a phosphodiester bond with a deoxynucleotide 220
 – formation of amide bonds 216
 – forming a glycosidic linkage 219
 – N-glycosidic bonds 216
 – N-glycosylation of a guanine base followed by β -elimination 249
 – hydrolysis and ligation of phosphodiester bonds 211
 – 3'-5' ligase activity 247
 – ligation 71
 – ligation of DNA strands with 3' phosphorothioates 301
 – metallation of N-methylmesoporphyrin 220
 – Michael additions 212, 215, 221
 – S-Michael reaction 217
 – oxidation and reduction 218
 – oxidation of benzyl alcohol 214
 – P-O bonds 217
 – peptide bond formation 72
 – phosphoanhydride formation 217
 – phosphodiester bond cleavage 6
 – phosphodiester bond formation 6
 – phosphorylation 217
 – 5' phosphorylation of DNA 249
 – 5'-phosphothioester linkage 252
 – photoreaction 253

- porphyrin metallation 213, 218, 232
- redox reaction 111, 212, 216, 218, 221
- RNA cleavage 220
- RNA ligation 217, 220, 246
- RNA/DNA cleavage 217
- 5'-self-capping reaction 251
- thymine dimer repair 254
- *trans*-aminoacylation of a tRNA 219
- transesterification 217, 248
- transesterification reactions 215
- transfer of a γ -phosphate 249
- reduced sets of nucleotides 7
- renal clearance 135
- renal elimination 379
- renal filtration 381, 405
- replication–mutation matrix 30
- replicator 56
- reporter ribozyme 284-286
- respirable antisense oligonucleotides (RASONS) 386
- restenosis 403
- restenosis/intimal hyperplasia 349
- retinal pigment epithelium (RPE) 447
- retroviral frameshift element 99
- Rev response element (RRE) 145
- reverse Hoogsteen 167-168
- rheumatoid arthritis 142, 369
- ribosomal (rRNA) 72
- ribosome 16, 121, 126, 218-219, 462
 - antibiotics 119
 - peptide bond formation 125
 - peptidyltransferase loop 125
 - X-ray crystal structure 124
- ribozyme (metabolite-binding RNA) 11, 76, 79, 117, 191, 290
 - control of transcription termination 192
 - designed 47
 - expression platform 193, 199, 201
 - FMN 79
 - genetic control 192, 196, 198, 203
 - glucosamine 6-phosphate (GlcN6P) 79
 - intrinsic terminator 193, 199
 - natural aptamer 47, 192, 466
 - negative feedback loop 192
 - regulation of transcription termination 79
 - RNA aptamer-regulated mRNA translation 16
 - self-cleavage 203
 - self-induced RNA switch 47
 - tandem arrangement 201
 - thiamine 79
 - three-dimensional structure 197
 - transcription termination 193, 196
 - translation initiation 79, 193
- ribozyme specific for
 - S-adenosylmethionine (SAM) 192, 195
 - adenine 192, 194, 196, 199
 - adenosylcobalamin (AdoCbl) 195
 - coenzyme B₁₂ 194, 204
 - FMN 79, 194-195, 204
 - glucosamine 6-phosphate (GlcN6P) 79, 192, 194, 203
 - glycine 192, 194-195, 201-203
 - guanine 192, 194, 196-197, 204
 - hypoxanthine 196
 - lysine 192, 194
 - SAM I 194, 204
 - SAM II 194, 204
 - TPP 193-195
- ribozyme 3, 6-8, 19, 39, 41, 45-46, 56, 58, 61, 64, 68, 72, 77-80, 82-83, 95, 118, 170, 228, 290, 292-293, 300, 319, 398, 463, 466
 - adenine-dependent 77
 - ADH 78
 - aptamer-controlled 17
 - capping ribozyme 219
 - *cis*-acting 127
 - class I ligase 9, 13, 17
 - class I ligase-based polymerase 20
 - cofactor-assisted 56, 74
 - Diels-Alderase 212, 220-221, 224, 305, 427
 - group I intron 17, 58, 60, 76, 99, 116, 122, 126-127, 215, 291-292, 300, 308
 - group II intron 58, 215
 - hairpin 58, 59-61, 63, 76, 78, 215, 286, 292, 300
 - hammerhead 17-18, 58, 79, 215, 229, 291-292, 296-297, 301, 303-304, 306-308
 - hepatitis delta virus (HDV) ribozyme 58, 61, 126, 215, 224, 291-292, 300
 - L1 ligase 293-294, 296-297, 306-307
 - ligase 293, 299
 - mirror-image I-ribozyme 221
 - Neurospora varkud satellite (VS) ribozyme 58-59, 60-61, 63-64, 66, 69-71, 127, 215
 - nucleolytic 60
 - Pb²⁺-dependent RNA-cleaving ribozymes 229
 - peptide bond formation 72
 - peptidyltransferase ribozymes 305
 - processive polymerase activity 20
 - redox active ribozyme 220-221, 305
 - replicase 20
 - replicase activity 20
 - reporter ribozyme 285

- ribonuclease P 54, 58, 83, 215
- ribosome 218
- ribox02 305
- RNA ligase 49
- RNA self-splicing 54
- RNA-dependent RNA polymerase 11
- self-alkylating 99
- self-replicating ligase structures 17
- synthesis of acyl-coA 76
- synthesis of ribonucleotide monomers 16
- template-directed primer-extension activity 9
- tools in organic chemistry 211
- *trans*-acting 127
- *trans*-cleaving 58
- X-motif ribozymes 292
- L-RNA 334, 421, 434, 437
 - L-adenosine 434
 - L-cytidine 434
 - L-guanosine 434
 - L-uridine 434
- RNA interference (RNAi) 269
- RNA peptidation 83
- RNA polymerase 192
- RNA polymerization 29
- RNA replication 16
- RNA replicators 84
- RNA template 29
- RNA world 4, 50, 56, 69, 79, 84, 95, 102, 204, 212, 218, 220, 228
 - nucleotide coenzymes 54
- RNA–antibiotic interactions 118
- RNA-based metabolism 74
- RNA-guided metabolism 204
- RNAi; see siRNA (small interference RNA, RNAi)
- RNase footprinting 170, 179
- route of administration 382, 389, 391
 - intravenous administration 390-392
 - intravitreal injection 387, 398, 453
 - oral delivery 385
 - oral dosing 391
 - parenteral administration 382-383, 391
 - pulmonary delivery 386
 - topical administration 385
 - topical delivery 384
- S**
- S-adenosylmethionine 72
- safety pharmacology 388, 392
- sandwich approaches 325
- sandwich-type assay 303
- scFv, Fab, see antibody fragments (scFv, Fab)
- SCID mice 155
- secondary structure 38, 40, 46, 109, 120, 174, 197, 222, 234, 245, 248-249, 251-252, 255, 291, 299, 40
 - A=U base pair 39
 - active conformation 14
 - adenosine platform 167
 - Arrhenius-type kinetics 37
 - base pair stacking 39
 - base pairing 36, 47
 - base triplet 47
 - bipartite RNA structure 96
 - bulge 65, 170, 240, 285
 - cloverleaf structure 41-42
 - conformation space 47
 - conformations (meta)stable 47
 - DNA folding 38
 - DNA structures 38 ff.
 - double helices 39
 - double kissing complex 177
 - folding problem 45
 - free energy levels 37
 - G-quartet 98, 250, 312, 328-329
 - GNRA tetraloop 48
 - GTP-binding aptamers 12
 - hairpin 12, 36, 83, 127, 169, 170-171, 176, 186, 461
 - hairpin loop 39, 99
 - hexameric loop 171
 - in-line probing 196, 201
 - individual folding trajectory 37
 - internal bulge 99
 - internal loop 186
 - internal stem–tetraloop 13
 - inverse folding 35, 42, 49
 - kinetic folding 36, 37
 - kissing complex 170, 172-173, 176, 178, 184
 - loop–loop helix formation 178
 - loop–loop interaction 170, 173, 176, 178, 186
 - *m*-fold 64
 - minimum free energy (MFE) 33-34, 40, 47, 64, 67
 - non-canonical interactions 100, 170, 200
 - pseudo-knot 11, 34, 47, 58, 64, 99, 127, 180, 196, 282, 371
 - RNA folding 35, 45
 - RNA folding algorithm 58
 - RNA sequence–structure mapping 32
 - RNA structures 33 ff.
 - RNA–DNA cofolding 38
 - RNase S₁ analysis 126

- secondary structure prediction 35
 - stable internal stem–tetraloop 12
 - stable tetraloop 11, 48
 - stem–loop structure 192
 - stems 11
 - steric hindrance 39
 - suboptimal conformation 36-37
 - three stem junction 196
 - two-hairpin structure 177
 - unpaired loop 285
 - Vienna RNA package 35, 64
 - wobble pair 47
 - wobble-type pairings 11
 - selectivity 107
 - sense–antisense duplex 184
 - sensor; see biosensor (aptasensor, sensor)
 - septic shock 148, 157
 - sequence space 3, 13, 15, 31, 33, 39-40, 57
 - serine protease 149, 151
 - serum-stabilized aptamer 265
 - shape space 31
 - Shine–Dalgarno sequence 193
 - sialyl Lewis X (sLe^x) 155, 403
 - side-effects 313
 - signal transduction 271
 - single-chain antibody fragments (scFvs) 269, 370
 - siRNA (small interference RNA, RNAi) 170, 268, 284, 388, 437, 466
 - small-molecule drugs 311
 - solid-phase peptide synthesis 421, 428
 - specificity 135, 270, 372, 375, 450
 - Spiegelmer 181, 333, 355-356, 417, 423-425, 429, 433
 - adenosine 426, 438
 - arginine 426, 438
 - D-arginine 334, 340
 - biological stability 427
 - calcitonin gene-related peptide 1 (CGRP) 159, 430, 438
 - catalytically active spiegelmers 427
 - Ghrelin 139, 158, 431, 438
 - gonadotropin-releasing hormone (GnRH) 139, 159, 429, 431-432, 438
 - immunogenic potential 432
 - lock-and-key stereocomplementarity 422
 - neuropeptide calcitonin gene-related peptide 1 139
 - neuropeptide nociceptin/orphanin FQ 139
 - nociceptin/orphanin FQ (N/OFQ) 160, 430, 438
 - peptides 158
 - production 434
 - L-ribose 434
 - SEB 438
 - Spiegelmer technology 425
 - staphylococcal enterotoxin B (SEB) 429
 - Substance P 430, 438
 - toxicity 433
 - D-tyrosine 334
 - vasopressin 429, 438
 - spliceosome 16
 - splicing 116, 272
 - stacking 33
 - stereochemistry 418, 427
 - stereoselectivity 212
 - stochastic corrector model 54-56
 - stochastic model of species evolution 44
 - streptavidin–agarose 214
 - streptavidin–biotin 325, 330
 - streptomycin 116
 - StreptoTag 123
 - surface plasmon resonance (SPR) 303
 - surface plasmon resonance measurement 171
 - systemic administration 348
- t**
- T7 RNA polymerase 377, 380
 - Taq polymerase 20
 - TAR RNA 99-100, 131, 144, 170, 176, 181, 184
 - target validation 265, 267, 271, 273, 287
 - *in vivo* 266
 - disease pathology 266
 - target-to-hit 265
 - Tat 131
 - Tat–TAR interaction 378
 - Taxol 276
 - tenascin aptamer TTA1
 - clinical trials 360
 - fecal excretion 347
 - ⁶⁸Ga 360
 - ⁶⁸Ga-DO3A-TTA1 360
 - images of lung and breast tumors 360
 - intestinal uptake 347
 - ¹²⁵I-labeled 346
 - ^{99m}Tc-labeled 346, 348
 - labeled with ^{99m}Tc 360
 - LNA modification 347, 353
 - MAG₂ chelator 353
 - 2'-O-methyl 353
 - 2'-O-methyl modification 347
 - murine tenascin-C 360
 - PET 360

- renal clearance 348
 - SPECT 360
 - Tenascin-C 364, 367
 - tumor imaging in mice 350
 - tumor-to-organ ratio 348
 - tetracycline aptamer
 - regulation of translation 121
 - tetrameric aptamer 154
 - theophylline aptamer 113
 - allosteric hammerhead ribozyme 106
 - iterative computational deletion 106
 - molecular beacon 106
 - NMR 105
 - ribozyme ligase 106
 - structure 105
 - theophylline-responsive riboswitch 106
 - to regulate gene expression 106
 - thermodynamic equilibrium 195
 - thermodynamic stability 13
 - thermodynamics 33
 - thioaptamers 379
 - threose nucleic acid (TNA) 17, 20
 - thrombin 389
 - thrombin aptamer (ARC 183) 330, 373, 383, 389, 464
 - anticoagulant 400
 - biotinylated aptamer 378
 - CABG 400
 - clinical development 463
 - clinical trials 401
 - ligand in affinity capillary electrophoresis 336-339
 - NMR studies 400
 - non-nucleotide modifications 378
 - radioiodinated (¹²⁵I) aptamer 359
 - thrombocytopenia 152
 - thrombosis 349
 - thymine dimer 253
 - tissue penetration 345
 - tissue remodeling 157
 - TNA; see threose nucleic acid (TNA)
 - toxicity 397, 433
 - toxicology 388, 392
 - transfection 281
 - transfer RNA (tRNA) 45, 47, 71-72, 83-84, 116, 125, 131, 172, 219, 223, 229, 282, 299
 - transition state analog (TSAs) 212, 232
 - Transmissible spongiform encephalopathies (TSEs) 158
 - triple helix 168, 185
 - triplex 248
 - triplex-forming oligonucleotides 167
 - TSA; see transition state analog (TSA)
 - TTA1; see tenascin aptamer TTA1
 - tumor diagnosis 350
 - tumor immunotherapy 154
 - tumor model 144
 - tumor uptake 359, 366
 - tumor-to-blood ratio 366
 - tumors 273-274, 356
- u**
- UDPGT (uridine diphosphate glucuronyl transferase) 390
 - urinary excretion 345
 - 5'-UTR (5' untranslated region) 191, 192, 196, 201, 203
 - 5'-UTR intron 193
 - UV crosslinking 121
 - UV detection 331
 - UV irradiation 328
- v**
- vaccination 154
 - VEGF aptamer; see Macugen (pegaptanib sodium)
 - VEGF and human disease
 - age-related macular degeneration (AMD) 446
 - anti-VEGF therapy 456-457
 - cancer 445
 - diabetic retinopathy 448
 - neovascular AMD 456
 - neovascularization 451-452
 - pathologic neovascularization 451
 - physiologic neovascularization 451
 - regression of existing tumor vessels 450
 - VEGF and human physiology 449
 - VEGF inhibition 450
 - VEGF isoforms 449-452
 - VEGF pathway 464
 - VEGF therapeutic dilemma 449
 - VEGF-TRAP 450
 - wound-healing 449
 - viral entry 366
 - viral vectors 281
 - viral-cell adhesion 366
 - vitravene™ (fomivirsen) 387
 - volume of distribution 388, 396
- w**
- Warburg effect 350
 - Watson-Crick base pairing 167, 169, 199, 239, 241, 245, 306, 378
 - Wilms' tumor 274

x

- X-ray crystallography 167, 196, 200
 - bacteriophage MS2 coat protein 312
 - thrombin 312
 - transcription factor NFκB 312
- xenograft model 275

y

- yeast three-hybrid system 282